Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Aalto's bone lengthening treatment spinout Synoste has been snapped up after raising funding from investors including Evonik and Mectalent.

Parkwalk made the revelations in a bullish quarterly update that cited the UK government's interest in invigorating deep tech research amid covid-19.

LMU-founded antibody reagent supplier ChromoTek has been picked up after raising funding from Bayern Kapital and HTGF in 2010.

Parent company Legend Holdings contributed 25% of the total as early-stage investment arm Legend Star closed its fourth renminbi-denominated fund.

The small molecule cancer drug developer has launched with series A funding from investors including Partners HealthCare Innovation.

Evonik and Mectalent have exited the bone implant developer in an acquisition by Globus Medical that follows nearly $12m in funding.

The cancer and fibrosis drug developer's series D round was co-led by investors including Walvax Biotechnology and a fund management vehicle for Sunshine Insurance.

Takeda Ventures was among the investors as the cellular therapeutics developer launched with a round co-led by RA Capital Management and Atlas Venture.

Legend Capital has contributed to an eight-figure dollar round for the neurological surgery device provider that was led by Hillhouse Capital.